Drug
Vosaroxin clinical trials
Also written SNS-595 and Voreloxin.
- studies test it
- 17
- open now
- 1
- in phase 3
- 3
- first study started
- 2004
Keep track of what changes. Save the vosaroxin studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Other names
Combined with it in one product
Studies by the year they started
17 studies that test it; most in 2013 (3)
| Year | Studies |
|---|---|
| 2004 | 2 |
| 2005 | 2 |
| 2006 | 2 |
| 2007 | 1 |
| 2008 | 1 |
| 2010 | 1 |
| 2013 | 3 |
| 2014 | 1 |
| 2015 | 2 |
| 2016 | 1 |
| 2018 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 7
- Phase 2
- 11
- Phase 3
- 3
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 9 · Other 8
Sunesis Pharmaceuticals (9) · Vanderbilt-Ingram Cancer Center (1) · Washington University School of Medicine (1) · M.D. Anderson Cancer Center (1) · University of Ulm (1) · Weill Medical College of Cornell University (1) · University Hospital, Angers (1) · Hamid Sayar (1)
Often tested with
Tested in the same studies.
Cytarabine (4) · Azacitidine (2) · Decitabine (1) · Idarubicin (1) · Cyclosporine (1) · Mycophenolic Acid (1) · Dexamethasone (1) · Venetoclax (1)
Studies
Open first, then newest update. How each study uses vosaroxin is read from its arms, and is right about nine times in ten.
Testing it · 17
- Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CRRecruitingPhase 2/3University Hospital, AngersNCT02416388Written as vosaroxin
- Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid LeukemiaCompletedPhase 2Vanderbilt-Ingram Cancer CenterNCT02658487Written as Vosaroxin
- Vosaroxin and Azacitidine in Treating Patients With Myelodysplastic SyndromesCompletedPhase 1Washington University School of MedicineNCT01913951Written as vosaroxin
- Study of Vosaroxin and Decitabine in Older Patients With Acute Myeloid Leukemia and High-risk Myelodysplastic SyndromeCompletedPhase 1/2M.D. Anderson Cancer CenterNCT01893320Written as Vosaroxin
- Study of Vosaroxin With Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome With Excess Blasts-2CompletedPhase 2University of UlmNCT03338348Written as Vosaroxin
- Trial to Test the Effects of Adding 1 of 2 New Treatment Agents to Commonly Used Chemotherapy CombinationsStatus unknownPhase 2/3Cardiff UniversityNCT02272478Written as Arm B Vosaroxin and Decitabine
- Vosaroxin for Intermediate 2 or High-risk MDS After Failure With Hypomethylating Agent-based TherapyCompletedPhase 1/2Weill Medical College of Cornell UniversityNCT01980056Written as Vosaroxin
- Safety and Efficacy Clinical Study of SNS-595 for Second-Line Therapy in Patients With Advanced NSCLCCompletedPhase 2Sunesis PharmaceuticalsNCT00252382Written as SNS-595 Injection
- Study of Vosaroxin or Placebo in Combination With Cytarabine in Patients With First Relapsed or Refractory AMLCompletedPhase 3Sunesis PharmaceuticalsNCT01191801Written as vosaroxin + cytarabine
- Safety and Efficacy Clinical Study of SNS-595 in Patients With Advanced Small Cell Lung CancerCompletedPhase 2Sunesis PharmaceuticalsNCT00298896Written as SNS-595
- Safety and Tolerability Study of Voreloxin and Cytarabine Combination in Acute Myeloid Leukemia in HumansCompletedPhase 1/2Sunesis PharmaceuticalsNCT00541866Written as Voreloxin injection and cytarabine
- Study of Vosaroxin and Cytarabine for the Treatment of Adults 60 Years of Age or Older With Previously Untreated AMLTerminatedNot applicableHamid SayarNCT02485353Written as Vosaroxin and Cytarabine
- Safety and Efficacy Clinical Study of SNS-595 in Patients With Platinum-Resistant Ovarian CancerCompletedPhase 2Sunesis PharmaceuticalsNCT00408603Written as Voreloxin Injection
- Study of Voreloxin (Vosaroxin) in Older Patients With Untreated Acute Myeloid LeukemiaCompletedPhase 2Sunesis PharmaceuticalsNCT00607997Written as vosaroxin
- Safety Assessment of Two Schedules of Intravenous Infusions of SNS-595 for the Treatment of Hematologic MalignanciesCompletedPhase 1Sunesis PharmaceuticalsNCT00246662Written as Vosaroxin
- Safety Assessment of Weekly Intravenous Infusions of SNS-595 for the Treatment of Solid TumorsCompletedPhase 1Sunesis PharmaceuticalsNCT00094159Written as SNS-595
- Initial Safety Assessment of SNS-595 for the Treatment of Solid Tumors.CompletedPhase 1Sunesis PharmaceuticalsNCT00091585Written as SNS-595
Codes
What other systems call vosaroxin · ClinicalTrials.gg INT004639
- MeSH (NLM) C485113vosaroxinConfirmed NLM, Wikidata
- UNII (FDA) K6A90IIZ19VOSAROXINConfirmed FDA, NLM, Wikidata
- Wikidata Q18395775vosaroxinConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C95148VosaroxinOne source FDA
- DrugBank DB11999One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C485113 | vosaroxin | Confirmed NLM, Wikidata |
| UNII (FDA) | K6A90IIZ19 | VOSAROXIN | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q18395775 | vosaroxin | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C95148 | Vosaroxin | One source FDA |
| DrugBank | DB11999 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.